Revenues (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition

The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):

			Year Ended December 31,
	Over time	Point in time	2022		2021		2020
Gilead Collaboration
License to domvanalimab		*	$	-	$	329	$	-
License to zimberelimab		*		-		-		55
License and R&D services	*			74		1		-
Access rights	*			33		31		16
Taiho Collaboration
License to domvanalimab		*		-		15		-
Access rights	*			5		7		7
Total revenues			$	112	$	383	$	78

Summary of Revenue Recognized as a Result of Changes in Deferred Revenue

The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):

	Year Ended December 31,
	2022		2021		2020
Revenue recognized from amounts in deferred revenue at the beginning of the period	$	112	$	202	$	7

Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations

The following table summarizes the transaction price and the allocation of the transaction price to the performance obligations (in millions):

Transaction price	Amount
Deferred revenues as of December 21, 2021	$	165
Option payment for Domvanalimab		275
Option payment for Etrumadenant		250
Option payment for Quemliclustat		200
Total transaction price	$	890

Allocation to performance obligations	Distinct	Combined	Amount
Domvanalimab - License	*		$	329
Domvanalimab - R&D services	*			34
Etrumadenant - License and R&D services		*		219
Quemliclustat - License and R&D services		*		176
Zimberelimab - R&D and commercial services	*			11
Access rights	*			84
Option continuation periods	*			37
Total allocated transaction price			$	890